Therapeutic safety and effectiveness of dual oral therapy with Daclatasvir and Asunaprevir for chronic HCV patients with renal dysfunction

Abstract

We investigated the safety and effectiveness of the dual oral therapy with Daclatasvir (DCV) and Asunaprevir (ASV) for patients with renal dysfunction. This study enrolled 682 HCV genotype 1b patients treated with DCV and ASV and included 83 patients with eGFR less than 50 ml/min/1.73 m², and 17 patients with eGFR less than 30 ml/min/1.73 m². Serum creatinine and eGFR were not altered during the treatment and the rate of complications and viral response was similar between patients with renal dysfunction and patients without renal dysfunction. The treatment with DCV and ASV was well tolerated and safety enough even for the HCV patients with renal dysfunction and could be productive therapeutic option for aged patients that accounts many of patients with HCV genotype 1b infection in Japan.